var data={"title":"Chemical pleurodesis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chemical pleurodesis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/contributors\" class=\"contributor contributor_credentials\">John E Heffner, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/contributors\" class=\"contributor contributor_credentials\">V Courtney Broaddus, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/contributors\" class=\"contributor contributor_credentials\">Geraldine Finlay, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleurodesis is a procedure that obliterates the pleural space to prevent recurrent pleural effusion or recurrent pneumothorax. It is most commonly performed by draining the effusion or intrapleural air and then inducing intrapleural inflammation and fibrosis by either instilling a chemical irritant or performing mechanical abrasion.</p><p>The use of a chemical irritant is known as chemical pleurodesis. Common questions about chemical pleurodesis include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>What are the indications?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>What are the contraindications?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Which agent should be used?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>How is it performed?</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>What are the potential complications?</p><p/><p>Alternatives to chemical pleurodesis include mechanical abrasion (also termed dry abrasion) of the parietal pleura during thoracoscopy or thoracotomy or placement of a tunneled pleural catheter, which drains pleural fluid and may induce pleurodesis without instillation of a sclerosing agent. The indications, contraindications, choice of sclerosant, procedure, and complications of chemical pleurodesis will be reviewed here. The techniques of tube thoracostomy and pleural abrasion during thoracoscopy are discussed separately. (See <a href=\"topic.htm?path=placement-and-management-of-thoracostomy-tubes\" class=\"medical medical_review\">&quot;Placement and management of thoracostomy tubes&quot;</a> and <a href=\"topic.htm?path=primary-spontaneous-pneumothorax-in-adults#H19\" class=\"medical medical_review\">&quot;Primary spontaneous pneumothorax in adults&quot;, section on 'VATS pleurodesis'</a>.) The role of tunneled pleural catheters are discussed elsewhere. (See <a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of malignant pleural effusions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">INDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemical pleurodesis has been used to manage malignant pleural effusions, refractory nonmalignant pleural effusions, and pneumothorax.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Malignant effusion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Malignant pleural effusion is the most widely accepted indication for chemical pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/1\" class=\"abstract_t\">1</a>]. Identifying patients with malignant pleural effusions who should be considered for chemical pleurodesis and alternative options for managing malignant pleural effusions are discussed in detail elsewhere. (See <a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of malignant pleural effusions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Nonmalignant effusion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary therapy for nonmalignant pleural effusions is treatment of the underlying cause. Refractory nonmalignant pleural effusions sometimes require chemical pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/2-4\" class=\"abstract_t\">2-4</a>] although management with a tunneled pleural catheter has become an alternative approach [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Successful chemical pleurodesis has been reported in case reports of patients with pleural effusions caused by chronic ambulatory peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/6\" class=\"abstract_t\">6</a>], yellow nail syndrome [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/7\" class=\"abstract_t\">7</a>], chylothorax [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/8,9\" class=\"abstract_t\">8,9</a>], lupus pleuritis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/8,10\" class=\"abstract_t\">8,10</a>], and heart failure [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/11-13\" class=\"abstract_t\">11-13</a>]. Although there are reports of success in hepatic hydrothorax [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/5,8,11,14,15\" class=\"abstract_t\">5,8,11,14,15</a>], the rate of complications in pooled data from a systematic review was 82 percent [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/15\" class=\"abstract_t\">15</a>]. Tunneled pleural catheters without chemical sclerosant for patients with hepatic hydrothorax have been reported to cause spontaneous pleurodesis in 33 percent of patients after a mean time of insertion of 132 days [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The management of patients with refractory nonmalignant pleural effusion is discussed in detail separately. (See <a href=\"topic.htm?path=management-of-refractory-nonmalignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of refractory nonmalignant pleural effusions&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Pneumothorax</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thoracoscopic and chemical methods of pleurodesis successfully prevent the recurrence of primary and secondary spontaneous pneumothorax [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/17-20\" class=\"abstract_t\">17-20</a>]. However, thoracoscopy with mechanical pleurodesis has benefits over chemical pleurodesis because it allows for simultaneous inspection and resection of subpleural blebs. In addition, thoracoscopic mechanical pleurodesis, although requiring longer hospital stays, does not expose the patient to possible risks related to talc. Comparatively, evidence suggests a similar reduction in recurrence from thoracoscopy as compared with chemical pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/18,20\" class=\"abstract_t\">18,20</a>]. Thus, chemical pleurodesis is a reasonable option in those who prefer to avoid thoracoscopic surgery. </p><p>The management of spontaneous pneumothorax is discussed in detail elsewhere. (See <a href=\"topic.htm?path=primary-spontaneous-pneumothorax-in-adults\" class=\"medical medical_review\">&quot;Primary spontaneous pneumothorax in adults&quot;</a> and <a href=\"topic.htm?path=secondary-spontaneous-pneumothorax-in-adults\" class=\"medical medical_review\">&quot;Secondary spontaneous pneumothorax in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CONTRAINDICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pleurodesis will fail if the lung cannot fully expand to the chest wall (eg, trapped lung, interstitial pulmonary fibrosis, endobronchial obstruction) because successful pleurodesis requires contact of the visceral and parietal pleura. Chemical pleurodesis should therefore not be attempted when the lung does not fully expand after therapeutic thoracentesis. Patients whose lungs cannot fully expand usually have radiographic evidence of a pneumothorax after thoracentesis or experience chest discomfort during thoracentesis before all pleural fluid is drained [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung\" class=\"medical medical_review\">&quot;Diagnosis and management of pleural causes of unexpandable lung&quot;</a>.)</p><p>Before attempting pleural drainage, the clinician should evaluate the position of the mediastinum on the chest radiograph. Normally, the mediastinum will shift away from a large effusion. If the mediastinum is shifted toward the effusion, it likely indicates that the pleural pressure on the side with the effusion is more negative than that on the contralateral side. Trapped lung (with fibrotic inelastic visceral pleura), entrapped lung (with an ongoing inflammatory or malignant process restricting expansion), endobronchial obstruction, or malignant encasement of the lung should be suspected. Of note, these same conditions can also result in a midline mediastinum despite the presence of a large effusion [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/22\" class=\"abstract_t\">22</a>].</p><p>An additional way to assess whether a nonexpandable lung is contributing to a pleural effusion is to perform pleural manometry at the time of therapeutic thoracentesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/23,24\" class=\"abstract_t\">23,24</a>]. Manometry measures pleural pressure changes as pleural fluid is withdrawn and allows the calculation of pleural elastance at the end of the procedure. A final value for pleural elastance &ge;19 cm H<sub>2</sub>O per liter of fluid removed indicates a high likelihood of a nonexpandable lung and predicts pleurodesis failure. In centers that can standardize the technique and produce reliable results, pleural manometry provides helpful information to identify a nonexpandable lung [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/24\" class=\"abstract_t\">24</a>]. (See <a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung#H3\" class=\"medical medical_review\">&quot;Diagnosis and management of pleural causes of unexpandable lung&quot;, section on 'Diagnosis'</a>.)</p><p>No specific chemical characteristics of pleural fluid alone have sufficient predictive properties to be used to exclude individual patients from consideration for pleurodesis. In patients with malignant pleural effusions, certain chemical characteristics of pleural fluid make successful pleurodesis less likely, including pleural pH less than 7.20 or 7.30, pleural glucose less than 60 <span class=\"nowrap\">mg/dL,</span> and lactate dehydrogenase greater than 600 <span class=\"nowrap\">U/L</span> [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/25-28\" class=\"abstract_t\">25-28</a>]. A meta-analysis found that these criteria predicted pleurodesis failure with a sensitivity of only 55 to 59 percent and a specificity of 65 to 78 percent [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/29\" class=\"abstract_t\">29</a>]. An international study of patients diagnosed with malignant pleural effusions by video-assisted thoracoscopic surgery derived and validated a scoring system (the LENT prognostic score) to predict survival at one month, three months, and six months after diagnosis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/30\" class=\"abstract_t\">30</a>]. Elements used in the scoring system included pleural fluid lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) performance score, blood neutrophil-to-lymphocyte ratio, and tumor type. Whether the LENT prognostic score can be used to assist decision making in selecting patients for chemical pleurodesis remains to be established. Lower pleural fluid LDH concentrations (&lt;1500 International <span class=\"nowrap\">Units/L)</span> correlated with better survival in a case series of 74 patients with adenocarcinoma of the lung [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/31\" class=\"abstract_t\">31</a>]. Another study of 91 patients with malignant pleural effusions demonstrated that an ECOG score of 3 or 4 and previous chemotherapy or radiotherapy were independent predictors of a poor overall survival after video-assisted thoracoscopic surgery (VATS)-mediated <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/32\" class=\"abstract_t\">32</a>]. Among patients with malignant effusions due to non-small cell lung cancer, presence of epidermal growth factor receptor mutations predicted a high success rate for pleurodesis (&gt;90 percent) and median survival of 39 months when patients were treated sequentially with <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a> followed by VATS talc pleurodesis when disease progression was noted [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/33,34\" class=\"abstract_t\">33,34</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">CHOICE OF AGENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerous chemical irritants have been used to induce pleurodesis. These include talc, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a>, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, <a href=\"topic.htm?path=silver-nitrate-drug-information\" class=\"drug drug_general\">silver nitrate</a>, iodopovidone, <a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">bleomycin</a>, <em>Corynebacterium parvum</em> with parenteral <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> acetate, <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, <a href=\"topic.htm?path=fluorouracil-drug-information\" class=\"drug drug_general\">fluorouracil</a>, interferon beta, autologous blood, <a href=\"topic.htm?path=mitomycin-drug-information\" class=\"drug drug_general\">mitomycin</a> C, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, <a href=\"topic.htm?path=cytarabine-drug-information\" class=\"drug drug_general\">cytarabine</a>, <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a>, and <em>Streptococcus pyogenes</em> A3 (OK-432) [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/35-40\" class=\"abstract_t\">35-40</a>].</p><p>The characteristics of the agents most commonly used for chemical pleurodesis are described in the following sections. The choice among these agents is determined by several factors, including local expertise, availability of individual agents, and the underlying process for which chemical pleurodesis is needed. These issues are discussed further on the individual topic reviews. (See <a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of malignant pleural effusions&quot;</a> and <a href=\"topic.htm?path=management-of-refractory-nonmalignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of refractory nonmalignant pleural effusions&quot;</a> and <a href=\"topic.htm?path=primary-spontaneous-pneumothorax-in-adults\" class=\"medical medical_review\">&quot;Primary spontaneous pneumothorax in adults&quot;</a> and <a href=\"topic.htm?path=secondary-spontaneous-pneumothorax-in-adults\" class=\"medical medical_review\">&quot;Secondary spontaneous pneumothorax in adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Talc &ndash; Talc, a trilayered, magnesium sheet silicate, is the most effective and most commonly used agent. In two systematic reviews, talc was the chemical agent that most frequently resulted in successful pleurodesis (no recurrence of pleural fluid) [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/35,41\" class=\"abstract_t\">35,41</a>]. Numerous additional studies have confirmed that talc is the most effective agent for pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/42\" class=\"abstract_t\">42</a>], including two meta-analyses [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/43,44\" class=\"abstract_t\">43,44</a>]. Taken together, these studies indicate that successful pleurodesis occurs in greater than 90 percent of patients treated with talc. However, such results have not been universal. One clinical trial of <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> reported a lower success rate of 78 percent, 30 days after pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"topic.htm?path=talc-pleurodesis#H2\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;, section on 'What is talc'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">Tetracycline</a> derivatives &ndash; Tetracycline is no longer available for pleurodesis in the United States; however, the tetracycline derivatives <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> and <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> are used for pleurodesis. Success rates with these agents in most reports are lower than those with talc, with recurrence rates of 13 to 35 percent [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/46,47\" class=\"abstract_t\">46,47</a>]. However, some clinicians prefer tetracycline derivatives for chemical pleurodesis in patients being treated for pneumothorax. (See <a href=\"topic.htm?path=primary-spontaneous-pneumothorax-in-adults#H20\" class=\"medical medical_review\">&quot;Primary spontaneous pneumothorax in adults&quot;, section on 'Chemical pleurodesis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=silver-nitrate-drug-information\" class=\"drug drug_general\">Silver nitrate</a> and iodopovidone &ndash; Silver nitrate and iodopovidone have also been used for chemical pleurodesis. However, larger studies of these agents are necessary before their use can be recommended.</p><p/><p class=\"bulletIndent1\">A randomized trial that compared <a href=\"topic.htm?path=silver-nitrate-drug-information\" class=\"drug drug_general\">silver nitrate</a> to talc enrolled 60 patients with a symptomatic malignant pleural effusion who were randomly assigned to receive 5 g of talc slurry or a 0.5 percent solution of silver nitrate [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/48\" class=\"abstract_t\">48</a>]. Both groups had similar efficacy at 30, 60, and 90 days, with no recurrence being observed in nearly all patients. Another randomized trial compared silver nitrate and <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> for 50 patients with malignant pleural effusions [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/49\" class=\"abstract_t\">49</a>]. Both agents had similar rates of early and late recurrences of pleural effusions, and patients treated with silver nitrate had a lower incidence of chest pain and fever. A systematic review of silver nitrate pleurodesis by chest catheter or thoracoscopy reported that silver nitrate had a good side-effect profile and equal efficacy to <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> in those studies that compared to two agents [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/50\" class=\"abstract_t\">50</a>]. </p><p/><p class=\"bulletIndent1\">The efficacy of iodopovidone for pleurodesis was examined in two separate case series; iodopovidone induced successful pleurodesis in 86 to 96 percent of patients [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/51,52\" class=\"abstract_t\">51,52</a>]. A randomized trial that enrolled 39 patients with malignant pleural effusions compared talc slurry (21 patients) and iodopovidone (18 patients) instilled through a chest tube [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/53\" class=\"abstract_t\">53</a>]. No differences were noted in the number of patients who failed pleurodesis in the talc (four patients) as compared with the iodopovidone (five patients) group. Another randomized trial compared two concentrations of iodopovidone (1 versus 2 percent) in 60 patients with malignant pleural effusions mainly due to breast cancer with the purpose of systematically identifying adverse effects [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/54\" class=\"abstract_t\">54</a>]. All but two patients had a successful pleurodesis. Pleuritic chest pain attributable to the pleurodesis was the most common adverse event occurring in 55 percent with 11 percent of the 60 patients having severe pain. The pain resolved within several hours after pleurodesis. Forty-one patients developed hypertensive spikes with 10 serious events, but none required therapy and were attributed to anxiety. Four patients developed hypotension with one serious event. Five patients experienced subclinical hypothyroidism 30 days after pleurodesis that resolved without treatment. Transient mild changes in blood tests of liver enzymes, electrolytes, and C-reactive protein were not considered clinically important.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=bleomycin-drug-information\" class=\"drug drug_general\">Bleomycin</a> &ndash; Bleomycin is used less commonly for pleurodesis because of systemic toxicity and cost.</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">PATIENT PREPARATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Each patient's medications should be reviewed prior to performing pleurodesis. Concomitant use of glucocorticoids may decrease the success of chemical pleurodesis, because pleurodesis requires pleural inflammation and glucocorticoids are potent antiinflammatory agents [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/55-57\" class=\"abstract_t\">55-57</a>]. Previously, concern existed that nonsteroidal anti-inflammatory agents decreased the likelihood of a successful pleurodesis, but a study demonstrated no negative effects [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/58\" class=\"abstract_t\">58</a>]. In our practice, we reduce or hold a patient's glucocorticoids 24 to 48 hours prior to pleurodesis if possible.</p><p>Systemic anticoagulation is generally reversed for placement of a chest tube; it is not necessary to hold anticoagulation for chemical pleurodesis once the chest tube is in place.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">PROCEDURE VIA CHEST TUBE OR CATHETER</span></p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Pleural drainage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In preparation for pleurodesis for pleural effusion, the pleural space is drained by tube thoracostomy, using a small bore (12 to 14 Fr) catheter or tunneled pleural catheter (15.5 Fr) if one is already in place [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/59\" class=\"abstract_t\">59</a>]. The relative advantages and disadvantages of small bore versus large bore (24 to 32 Fr) chest tubes remain controversial [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/60-63\" class=\"abstract_t\">60-63</a>]. A randomized trial, however, that compared 12 Fr versus 24 Fr chest tubes found only a modest decrease in pain with the smaller tube but a higher pleurodesis failure rate with the smaller (30 percent) as compared with the larger (24 percent) tubes [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/58\" class=\"abstract_t\">58</a>]. We use small bore catheters because differences in outcomes relative to large bore tubes are modest, and we find small bore catheters better tolerated during insertion. (See <a href=\"topic.htm?path=placement-and-management-of-thoracostomy-tubes#H4\" class=\"medical medical_review\">&quot;Placement and management of thoracostomy tubes&quot;, section on 'Preparation'</a>.) </p><p>Previously, it was common practice to delay pleurodesis until daily chest tube drainage was less than 150 mL. However, this delay appears to be unnecessary as noted in two small randomized trials and a case series [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/64-66\" class=\"abstract_t\">64-66</a>]. In one study, for example, 25 patients with malignant pleural effusions were randomly assigned to standard (15 patients) or short-term (10 patients) protocols [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/64\" class=\"abstract_t\">64</a>]. In the standard protocol, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> was instilled only after the lung had completely expanded and the chest tube drainage was less than 150 mL per day. In the short-term protocol, the same dose of tetracycline was instilled as soon as there was complete lung expansion, which was usually within 24 hours. Pleurodesis was successful in 80 percent of patients in both groups.</p><p>Case series support the feasibility of performing chemical pleurodesis via tunneled pleural catheters. One study reported successful pleurodesis in 92 percent of patients undergoing the instillation of talc slurry through a tunneled pleural catheter [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/67\" class=\"abstract_t\">67</a>].</p><p>When pleurodesis is performed for pneumothorax, pleural air is drained until the lung is fully re-expanded.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Analgesia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemical pleurodesis is often painful; patients are usually pretreated with parenteral doses of an opiate (eg, <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a>) and an <span class=\"nowrap\">anxiolytic/amnestic</span> agent (eg, <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a>). Additionally, the British Thoracic Society guidelines for managing malignant pleural effusions recommend that <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> (3 <span class=\"nowrap\">mg/kg;</span> maximum 250 mg) should be instilled intrapleurally, just before administration of the sclerosant [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/68\" class=\"abstract_t\">68</a>]. Postprocedure analgesia should be provided as necessary to maintain comfort.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Sclerosant agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We typically perform chemical pleurodesis using talc because of its demonstrated efficacy. As noted above, chemical pleurodesis can be performed using any of a number of different chemical agents, the most common of which are talc and the <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> derivative, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Talc</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemical pleurodesis with talc can be accomplished with similar efficacy using insufflation (also called poudrage) during a thoracoscopy procedure or with slurry via tube thoracostomy as described above. Generally, the dose of talc administered intrapleurally is 4 g for insufflation and 5 g for slurry. When possible, size-calibrated talc that contains less than 10 percent of small particles (eg, 5 to 10 microns in diameter) should be used. Further details about the two procedures, talc doses, and analgesia are provided separately. (See <a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Doxycycline</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The typical dose of <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> used for intrapleural instillation is 500 mg dissolved in a total volume of 50 mL of normal saline [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/69,70\" class=\"abstract_t\">69,70</a>].</p><p><a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">Doxycycline</a> pleurodesis is often painful, although not more painful than other pleural sclerosants [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/43\" class=\"abstract_t\">43</a>]. Some practitioners add a local analgesic agent (eg, <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>, 25 mL [250 mg] of a 1 percent solution, or <a href=\"topic.htm?path=mepivacaine-drug-information\" class=\"drug drug_general\">mepivacaine</a>, 20 mL [400 mg] of 2 percent solution) to the doxycycline solution, although data supporting this are lacking [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/70,71\" class=\"abstract_t\">70,71</a>]. Systemic absorption of the local anesthetic may be significant. In addition to local analgesia, systemic administration of an analgesic agent is usually necessary.</p><p>At least one case of acute <span class=\"nowrap\">hypoxic/hypercapnic</span> respiratory failure has been reported after pleurodesis with <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> (300 mg) [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/72\" class=\"abstract_t\">72</a>]. Chest radiograph showed no pulmonary opacities and the presence of high peak ventilator pressures suggested acute bronchospasm due to an anaphylactic reaction. The patient improved in a few hours with ventilatory support and bronchodilator therapy.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Technique</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chemical pleurodesis may be performed at the time of thoracoscopy, at the bedside in the hospital, or in an outpatient clinic. Talc insufflation, which is performed during thoracoscopy, is described in detail separately. (See <a href=\"topic.htm?path=talc-pleurodesis#H15\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;, section on 'Talc insufflation'</a>.)</p><p>When chemical pleurodesis is performed at the bedside via tube thoracostomy or a tunneled pleural catheter (eg, instillation of talc slurry or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>), the usual protocol is as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Document good apposition of the pleural surfaces by chest radiograph.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ascertain adequate patient comfort and pain prevention, including intrapleural <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Administer the sclerosant agent (eg, talc, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>) via the chest catheter. (See <a href=\"topic.htm?path=talc-pleurodesis#H18\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;, section on 'Talc slurry'</a> and <a href=\"#H14\" class=\"local\">'Doxycycline'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pleural fluid drainage through the chest catheter should be discontinued for one to two hours following instillation of the chemical irritant. Talc slurry distributes poorly; therefore, some clinicians rotate the patient. However, there is no evidence that such rotation improves the probability of successful pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/35\" class=\"abstract_t\">35</a>]. Studies with <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> also show no need to rotate the patient [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/73,74\" class=\"abstract_t\">73,74</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After the catheter has been reopened, the results of passive drainage are observed. Some clinicians apply chest catheter suction (-20 cm H<sub>2</sub>O) for at least 24 hours if drainage is sluggish and the lung is slow to re-expand to the chest wall.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The traditional approach is to leave the chest tube in place until drainage is less than approximately 150 mL per 24 hours, although there are no scientific data to support this approach. The rationale is that ongoing pleural drainage helps to maintain apposition of the pleural surfaces and the chest tube is in place should repeat pleurodesis be needed. For example, if drainage is greater than 150 mL over 24 hours, repeat pleurodesis may be considered after 48 to 72 hours. Alternatively, some clinicians remove the chest tube within 24 hours after the instillation of talc or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, based on two small randomized trials showing no difference between the two approaches [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/64,75\" class=\"abstract_t\">64,75</a>]. The largest trial randomly assigned 41 patients with a malignant pleural effusion to have their chest tube removed either 24 or 72 hours after <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a>; there was no difference in the success rate between the two groups [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/75\" class=\"abstract_t\">75</a>]. Pending larger studies, we suggest leaving the chest tube in place until the rate of drainage of pleural fluid is &lt;150 <span class=\"nowrap\">mL/day</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If pleural fluid production persists despite chemical pleurodesis, use of a tunneled pleural catheter or thoracoscopic pleurodesis can be considered for secondary management. The options are discussed separately. (See <a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of malignant pleural effusions&quot;</a> and <a href=\"topic.htm?path=management-of-refractory-nonmalignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of refractory nonmalignant pleural effusions&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common adverse sequelae of chemical pleurodesis are fever, pain, and GI symptoms [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/43\" class=\"abstract_t\">43</a>]. Pain can be treated with opioids with the addition, if necessary, of nonsteroidal anti-inflammatory agents, which do not decrease the rate of success of pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/58\" class=\"abstract_t\">58</a>]. Far less commonly, patients may experience respiratory failure, cardiovascular complications, a systemic inflammatory response, empyema, decreased lung volume, and dissemination of the chemical agent. Based on a meta-analysis (n = 1499), mortality is not increased among patients undergoing <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> for a malignant pleural effusion compared with tube drainage alone or use of other sclerosants (eg, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, <a href=\"topic.htm?path=mitoxantrone-drug-information\" class=\"drug drug_general\">mitoxantrone</a>) [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Most of the complications of pleurodesis appear to be related to the sclerosing process (eg, pain, cardiovascular side effects, systemic inflammation, empyema) and are likely to occur with all sclerosants, although some appear to be sclerosant- and dose-specific. As an example, increased systemic exposure to talc (eg, using more than 5 grams) appears to increase the risk of adverse sequelae, but does not increase the success rate. (See <a href=\"topic.htm?path=talc-pleurodesis#H22\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;, section on 'Complications and safety'</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Respiratory failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The complication of acute respiratory failure, although rare, is more commonly seen after <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> compared with other sclerosant agents. It is unlikely that the method of administration (insufflation versus slurry) plays a major role in the development of respiratory failure; however, the dose and mean particle size of talc may be important, because smaller particles can present an increased risk. This is discussed in detail separately. (See <a href=\"topic.htm?path=talc-pleurodesis#H22\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;, section on 'Complications and safety'</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Cardiovascular</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cardiovascular complications, such as arrhythmias, cardiac arrest, chest pain, myocardial infarction, and hypotension, have been reported following pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/55,76\" class=\"abstract_t\">55,76</a>]. However, it is unclear whether these complications are a result of the surgical procedure, co-morbid conditions, or the chemical irritant.</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Inflammation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A mild systemic inflammatory reaction is common following chemical pleurodesis [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/76\" class=\"abstract_t\">76</a>]. As an example, in a retrospective study of 35 patients, patients who received talc insufflation via thoracoscopy had an increased temperature, white blood cell count, and C-reactive protein level compared to patients that underwent thoracoscopy alone [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Empyema</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bacterial empyema has been reported following pleurodesis using talc slurry (0 to 11 percent), talc insufflation (0 to 3 percent), or rarely <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/78,79\" class=\"abstract_t\">78,79</a>]. Local site infection is uncommon.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Dissemination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dissemination of talc into BAL fluid and multiple organs has been noted [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/80-82\" class=\"abstract_t\">80-82</a>]. The dissemination of talc into extrapulmonary organs appears to be dose-related [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Cancer</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A link between talc and cancer has been reported in individuals who mine and process talc [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/84\" class=\"abstract_t\">84</a>]. This association has been attributed to asbestos within the talc. As a result, there is a theoretical concern that <a href=\"topic.htm?path=talc-sterile-drug-information\" class=\"drug drug_general\">talc pleurodesis</a> could place the patient at increased risk for mesothelioma or lung cancer [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/2\" class=\"abstract_t\">2</a>]. However, the incidence of malignancy is not increased in patients who undergo talc pleurodesis and talc used for medical purposes is asbestos-free [<a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/85,86\" class=\"abstract_t\">85,86</a>].</p><p class=\"headingAnchor\" id=\"H3418417165\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-pleural-effusion\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Pleural effusion&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malignant pleural effusion is the most common and widely accepted indication for chemical pleurodesis. In addition, chemical pleurodesis is sometimes used to manage refractory nonmalignant pleural effusions, recurrent primary spontaneous pneumothorax, and secondary spontaneous pneumothorax. (See <a href=\"#H2\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest systemic glucocorticoid therapy be reduced or temporarily discontinued if possible prior to chemical pleurodesis (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We typically hold these medications for 24 to 48 hours prior to pleurodesis. (See <a href=\"#H8\" class=\"local\">'Patient preparation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The sclerosant agents used most commonly are talc and <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>. Talc slurry administered via chest tube appears equally effective compared with aerosolized talc administered via insufflation during thoracoscopy (also called poudrage). Doxycycline is a less effective alternative to talc. Chemical sclerosant can also be instilled through a tunneled pleural catheter. (See <a href=\"#H12\" class=\"local\">'Sclerosant agents'</a> above and <a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">&quot;Talc pleurodesis&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After instillation of the sclerosant agent (eg, talc or <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>), the chest catheter drainage is discontinued for one to two hours, then drainage is resumed. We suggest leaving the chest catheter in place until fluid drainage is less than 150 mL per day rather than removal within the first 24 hours (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H15\" class=\"local\">'Technique'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common short term adverse effects of chemical pleurodesis include pain, fever, and gastrointestinal symptoms. More rare adverse effects include respiratory failure, cardiovascular complications, a mild systemic inflammatory reaction, and empyema. (See <a href=\"#H16\" class=\"local\">'Complications'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/1\" class=\"nounderline abstract_t\">Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008; 83:235.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/2\" class=\"nounderline abstract_t\">Ghio AJ, Roggli V, Light RW. Talc should not be used for pleurodesis in patients with nonmalignant pleural effusions. Am J Respir Crit Care Med 2001; 164:1741; author reply 1741.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/3\" class=\"nounderline abstract_t\">Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/4\" class=\"nounderline abstract_t\">Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/5\" class=\"nounderline abstract_t\">Freeman RK, Ascioti AJ, Dake M, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion. Ann Thorac Surg 2014; 97:1872.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/6\" class=\"nounderline abstract_t\">Szeto CC, Chow KM. Pathogenesis and management of hydrothorax complicating peritoneal dialysis. Curr Opin Pulm Med 2004; 10:315.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/7\" class=\"nounderline abstract_t\">Maldonado F, Tazelaar HD, Wang CW, Ryu JH. Yellow nail syndrome: analysis of 41 consecutive patients. Chest 2008; 134:375.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/8\" class=\"nounderline abstract_t\">Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/9\" class=\"nounderline abstract_t\">Akin H, Olcmen A, Isgorucu O, et al. Approach to patients with chylothorax complicating pulmonary resection. Thorac Cardiovasc Surg 2012; 60:135.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/10\" class=\"nounderline abstract_t\">Breuer GS, Deeb M, Fisher D, Nesher G. Therapeutic options for refractory massive pleural effusion in systemic lupus erythematosus: a case study and review of the literature. Semin Arthritis Rheum 2005; 34:744.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/11\" class=\"nounderline abstract_t\">Bhatnagar R, Reid ED, Corcoran JP, et al. Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice. Thorax 2014; 69:959.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/12\" class=\"nounderline abstract_t\">Patil M, Dhillon SS, Attwood K, et al. Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis. Chest 2017; 151:626.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/13\" class=\"nounderline abstract_t\">Majid A, Kheir F, Fashjian M, et al. Tunneled Pleural Catheter Placement with and without Talc Poudrage for Treatment of Pleural Effusions Due to Congestive Heart Failure. Ann Am Thorac Soc 2016; 13:212.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/14\" class=\"nounderline abstract_t\">Temes RT, Davis MS, Follis FM, et al. Videothoracoscopic treatment of hepatic hydrothorax. Ann Thorac Surg 1997; 64:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/15\" class=\"nounderline abstract_t\">Hou F, Qi X, Guo X. Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis. Dig Dis Sci 2016; 61:3321.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/16\" class=\"nounderline abstract_t\">Chen A, Massoni J, Jung D, Crippin J. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. A Pilot Study. Ann Am Thorac Soc 2016; 13:862.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/17\" class=\"nounderline abstract_t\">Gy&ouml;rik S, Erni S, Studler U, et al. Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007; 29:757.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/18\" class=\"nounderline abstract_t\">Chen JS, Hsu HH, Huang PM, et al. Thoracoscopic pleurodesis for primary spontaneous pneumothorax with high recurrence risk: a prospective randomized trial. Ann Surg 2012; 255:440.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/19\" class=\"nounderline abstract_t\">Chen JS, Chan WK, Tsai KT, et al. Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial. Lancet 2013; 381:1277.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/20\" class=\"nounderline abstract_t\">Sepehripour AH, Nasir A, Shah R. Does mechanical pleurodesis result in better outcomes than chemical pleurodesis for recurrent primary spontaneous pneumothorax? Interact Cardiovasc Thorac Surg 2012; 14:307.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/21\" class=\"nounderline abstract_t\">Doelken P. Clinical implications of unexpandable lung due to pleural disease. Am J Med Sci 2008; 335:21.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/22\" class=\"nounderline abstract_t\">Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med 2007; 13:312.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/23\" class=\"nounderline abstract_t\">Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/24\" class=\"nounderline abstract_t\">Feller-Kopman D, Parker MJ, Schwartzstein RM. Assessment of pleural pressure in the evaluation of pleural effusions. Chest 2009; 135:201.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/25\" class=\"nounderline abstract_t\">Antunes G, Neville E. Management of malignant pleural effusions. Thorax 2000; 55:981.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/26\" class=\"nounderline abstract_t\">Sahn SA, Good JT Jr. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988; 108:345.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/27\" class=\"nounderline abstract_t\">Mart&iacute;nez-Morag&oacute;n E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65:108.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/28\" class=\"nounderline abstract_t\">Rodr&iacute;guez-Panadero F, L&oacute;pez Mej&iacute;as J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139:663.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/29\" class=\"nounderline abstract_t\">Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117:87.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/30\" class=\"nounderline abstract_t\">Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69:1098.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/31\" class=\"nounderline abstract_t\">Verma A, Phua CK, Sim WY, et al. Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion. Medicine (Baltimore) 2016; 95:e3996.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/32\" class=\"nounderline abstract_t\">Yoon DW, Cho JH, Choi YS, et al. Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion. Thorac Cancer 2016; 7:393.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/33\" class=\"nounderline abstract_t\">Lin JB, Lai FC, Li X, et al. Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation. J Drug Target 2017; 25:119.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/34\" class=\"nounderline abstract_t\">Verma A, Chopra A, Lee YW, et al. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. Curr Drug Discov Technol 2016; 13:68.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/35\" class=\"nounderline abstract_t\">Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29:829.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/36\" class=\"nounderline abstract_t\">Yoshida K, Sugiura T, Takifuji N, et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 2007; 58:362.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/37\" class=\"nounderline abstract_t\">Balassoulis G, Sichletidis L, Spyratos D, et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol 2008; 31:384.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/38\" class=\"nounderline abstract_t\">Caglayan B, Torun E, Turan D, et al. Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Ann Surg Oncol 2008; 15:2594.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/39\" class=\"nounderline abstract_t\">Salomaa ER, Pulkki K, Helenius H. Pleurodesis with doxycycline or Corynebacterium parvum in malignant pleural effusion. Acta Oncol 1995; 34:117.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/40\" class=\"nounderline abstract_t\">Terra RM, Kim SY, Pego-Fernandes PM, et al. Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol 2011; 18:1145.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/41\" class=\"nounderline abstract_t\">Clive AO, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; :CD010529.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/42\" class=\"nounderline abstract_t\">Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/43\" class=\"nounderline abstract_t\">Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; :CD002916.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/44\" class=\"nounderline abstract_t\">Xia H, Wang XJ, Zhou Q, et al. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One 2014; 9:e87060.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/45\" class=\"nounderline abstract_t\">Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/46\" class=\"nounderline abstract_t\">Almind M, Lange P, Viskum K. Spontaneous pneumothorax: comparison of simple drainage, talc pleurodesis, and tetracycline pleurodesis. Thorax 1989; 44:627.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/47\" class=\"nounderline abstract_t\">Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest 1994; 105:1743.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/48\" class=\"nounderline abstract_t\">Paschoalini Mda S, Vargas FS, Marchi E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128:684.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/49\" class=\"nounderline abstract_t\">Tabatabaei SA, Hashemi SM, Kamali A. Silver nitrate versus tetracycline in pleurodesis for malignant pleural effusions; a prospective randomized trial. Adv Biomed Res 2015; 4:178.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/50\" class=\"nounderline abstract_t\">Bucknor A, Harrison-Phipps K, Davies T, Toufektzian L. Is silver nitrate an effective means of pleurodesis? Interact Cardiovasc Thorac Surg 2015; 21:521.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/51\" class=\"nounderline abstract_t\">Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology 2006; 11:105.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/52\" class=\"nounderline abstract_t\">Olivares-Torres CA, Laniado-Labor&iacute;n R, Ch&aacute;vez-Garc&iacute;a C, et al. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002; 122:581.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/53\" class=\"nounderline abstract_t\">Ibrahim IM, Dokhan AL, El-Sessy AA, Eltaweel MF. Povidone-iodine pleurodesis versus talc pleurodesis in preventing recurrence of malignant pleural effusion. J Cardiothorac Surg 2015; 10:64.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/54\" class=\"nounderline abstract_t\">Andrade Neto JD, Terra RM, Teixeira RM, et al. Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion. Respiration 2015; 90:369.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/55\" class=\"nounderline abstract_t\">Kennedy L, Rusch VW, Strange C, et al. Pleurodesis using talc slurry. Chest 1994; 106:342.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/56\" class=\"nounderline abstract_t\">Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998; 157:1441.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/57\" class=\"nounderline abstract_t\">Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg 2004; 28:749.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/58\" class=\"nounderline abstract_t\">Rahman NM, Pepperell J, Rehal S, et al. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA 2015; 314:2641.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/59\" class=\"nounderline abstract_t\">Maskell N, British Thoracic Society Pleural Disease Guideline Group. British Thoracic Society Pleural Disease Guidelines--2010 update. Thorax 2010; 65:667.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/60\" class=\"nounderline abstract_t\">Lee HJ, Feller-Kopman DJ. Rebuttal From Drs Lee and Feller-Kopman. Chest 2015; 148:13.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/61\" class=\"nounderline abstract_t\">Gillespie CT, DeCamp MM. Rebuttal From Drs Gillespie and DeCamp. Chest 2015; 148:14.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/62\" class=\"nounderline abstract_t\">Lee HJ, Feller-Kopman DJ. POINT: Should Small-Bore Pleural Catheter Placement Be the Preferred Initial Management for Malignant Pleural Effusions? Yes. Chest 2015; 148:9.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/63\" class=\"nounderline abstract_t\">Gillespie CT, DeCamp MM. COUNTERPOINT: Should Small-Bore Pleural Catheter Placement Be the Preferred Initial Management for Malignant Pleural Effusions? No. Chest 2015; 148:11.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/64\" class=\"nounderline abstract_t\">Villanueva AG, Gray AW Jr, Shahian DM, et al. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994; 49:23.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/65\" class=\"nounderline abstract_t\">Yildirim E, Dural K, Yazkan R, et al. Rapid pleurodesis in symptomatic malignant pleural effusion. Eur J Cardiothorac Surg 2005; 27:19.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/66\" class=\"nounderline abstract_t\">Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions. Chest 2003; 123:1895.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/67\" class=\"nounderline abstract_t\">Ahmed L, Ip H, Rao D, et al. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. Chest 2014; 146:e190.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/68\" class=\"nounderline abstract_t\">Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58 Suppl 2:ii29.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/69\" class=\"nounderline abstract_t\">Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86:1992.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/70\" class=\"nounderline abstract_t\">Porcel JM, Salud A, Nabal M, et al. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer 2006; 14:475.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/71\" class=\"nounderline abstract_t\">Sherman S, Ravikrishnan KP, Patel AS, Seidman JC. Optimum anesthesia with intrapleural lidocaine during chemical pleurodesis with tetracycline. Chest 1988; 93:533.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/72\" class=\"nounderline abstract_t\">DiBardino DJ, Vanatta JM, Fagan SP, Awad SS. Acute respiratory failure after pleurodesis with doxycycline. Ann Thorac Surg 2002; 74:257.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/73\" class=\"nounderline abstract_t\">Lorch DG, Gordon L, Wooten S, et al. Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest 1988; 93:527.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/74\" class=\"nounderline abstract_t\">Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993; 104:1763.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/75\" class=\"nounderline abstract_t\">Goodman A, Davies CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. Lung Cancer 2006; 54:51.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/76\" class=\"nounderline abstract_t\">Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170:377.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/77\" class=\"nounderline abstract_t\">Froudarakis ME, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006; 129:356.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/78\" class=\"nounderline abstract_t\">Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 1994; 106:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/79\" class=\"nounderline abstract_t\">Abraham G, Cherian JH, Gopalakrishnan TJ. Pyopneumothorax with bronchofleural fistula following tetracycline pleurodesis in a patient on CAPD. Perit Dial Int 1992; 12:327.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/80\" class=\"nounderline abstract_t\">de Campos JR, Vargas FS, de Campos Werebe E, et al. Thoracoscopy talc poudrage : a 15-year experience. Chest 2001; 119:801.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/81\" class=\"nounderline abstract_t\">Campos JR, Werebe EC, Vargas FS, et al. Respiratory failure due to insufflated talc. Lancet 1997; 349:251.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/82\" class=\"nounderline abstract_t\">Kennedy L, Harley RA, Sahn SA, Strange C. Talc slurry pleurodesis. Pleural fluid and histologic analysis. Chest 1995; 107:1707.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/83\" class=\"nounderline abstract_t\">Montes JF, Ferrer J, Villarino MA, et al. Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am J Respir Crit Care Med 2003; 168:348.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/84\" class=\"nounderline abstract_t\">Kleinfeld M, Messite J, Kooyman O, Zaki MH. Mortality among talc miners and millers in New York State. Arch Environ Health 1967; 14:663.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/85\" class=\"nounderline abstract_t\">Lange P, Mortensen J, Groth S. Lung function 22-35 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage. Thorax 1988; 43:559.</a></li><li><a href=\"https://www.uptodate.com/contents/chemical-pleurodesis/abstract/86\" class=\"nounderline abstract_t\">A survey of the long-term effects of talc and kaolin pleurodesis. Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit. Br J Dis Chest 1979; 73:285.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6695 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H24\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">INDICATIONS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Malignant effusion</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Nonmalignant effusion</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Pneumothorax</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">CONTRAINDICATIONS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">CHOICE OF AGENT</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">PATIENT PREPARATION</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">PROCEDURE VIA CHEST TUBE OR CATHETER</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Pleural drainage</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Analgesia</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Sclerosant agents</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Talc</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Doxycycline</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">Technique</a></li></ul></li><li><a href=\"#H16\" id=\"outline-link-H16\">COMPLICATIONS</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">Respiratory failure</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Cardiovascular</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Inflammation</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Empyema</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Dissemination</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Cancer</a></li></ul></li><li><a href=\"#H3418417165\" id=\"outline-link-H3418417165\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-pleural-causes-of-unexpandable-lung\" class=\"medical medical_review\">Diagnosis and management of pleural causes of unexpandable lung</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-malignant-pleural-effusions\" class=\"medical medical_review\">Management of malignant pleural effusions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-refractory-nonmalignant-pleural-effusions\" class=\"medical medical_review\">Management of refractory nonmalignant pleural effusions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=placement-and-management-of-thoracostomy-tubes\" class=\"medical medical_review\">Placement and management of thoracostomy tubes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-spontaneous-pneumothorax-in-adults\" class=\"medical medical_review\">Primary spontaneous pneumothorax in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=secondary-spontaneous-pneumothorax-in-adults\" class=\"medical medical_review\">Secondary spontaneous pneumothorax in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-pleural-effusion\" class=\"medical medical_society_guidelines\">Society guideline links: Pleural effusion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=talc-pleurodesis\" class=\"medical medical_review\">Talc pleurodesis</a></li></ul></div></div>","javascript":null}